Site Editor

Leo I. Gordon, MD, FACP


Tycel Phillips, MD: Update on Novel BTK Inhibitor for Marginal Zone Lymphoma

Posted: Tuesday, February 1, 2022

Tycel Phillips, MD, of the Rogel Cancer Center, University of Michigan, discusses what the phase II results of the CITADEL-204 study could mean for BTK inhibitor–naive patients with marginal zone lymphoma, who appeared to benefit from monotherapy with parsaclisib. This second-generation agent could have advantages over current therapies and may be a potential treatment option for those with relapsed or refractory disease.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.